PDGFRB and neoplasm: In the four groups of subcutaneous tumor models constructed with PDGFRβ-overexpressing cells, the expression of PDGFRβ in the Ezetimibe treatment group alone and the Ezetimibe combined with MK2206 treatment group was significantly lower than that in the MK2206 treatment group alone or the vehicle control group.